Hey A W, Browne C A, Thorburn G D
Department of Physiology, Monash University, Clayton, Victoria, Australia.
Endocrinology. 1988 Jan;122(1):12-21. doi: 10.1210/endo-122-1-12.
A high efficiency procedure for the purification to homogeneity of an ovine fetal somatomedin is described. Fetal sheep serum was used as the source material, and activity was followed throughout purification by an insulin-like growth factor (IGF) II RRA. IGF-II-like activity was initially enriched through binding at acid pH to a column of SP-Sephadex C-25 and elution with a neutral pH high-salt buffer. Further chromatography on SP-Sephadex resulted in a preparation containing less than 0.1% of the original serum protein content, but retaining much of the IGF-II-like activity. This enriched fetal IGF preparation was then purified to homogeneity using reverse phase HPLC. However, chromatography on an HPLC gel filtration column was found to be essential to ensure the stability of the purified peptide during storage, although this procedure did not result in any apparent increase in purification. The final yield of purified ovine fetal IGF was 80 micrograms from 400 ml fetal sheep serum. Only one polypeptide chain was detected during amino-terminal sequencing of the fetal somatomedin, and the preparation gave a single band on both gel electrophoresis and isoelectric focusing, indicating that the peptide was essentially pure. The sequence (eight amino acid residues) was identical to the equivalent sequence in IGF-II from human, rat, and bovine sources. In additional, amino acid analysis of the ovine fetal IGF showed close similarity to the amino acid content of IGF-II from other species. The mol wt of the purified peptide, estimated by HPLC gel filtration, was approximately 7000, close to that of previously purified somatomedins, and the isoelectric point, obtained by chromatofocusing, was around pH 6.8. Thus, the purified ovine fetal somatomedin appears to be similar to IGF-II from other species, and may be the ovine homolog of human IGF-II.
本文描述了一种高效纯化绵羊胎儿生长调节素至同质的方法。以胎羊血清作为原料,在整个纯化过程中通过胰岛素样生长因子(IGF)II放射受体分析(RRA)追踪活性。IGF-II样活性最初通过在酸性pH下与SP-葡聚糖凝胶C-25柱结合,并使用中性pH高盐缓冲液洗脱来富集。在SP-葡聚糖凝胶上进一步色谱分离得到一种制剂,其蛋白质含量低于原始血清蛋白含量的0.1%,但保留了大部分IGF-II样活性。然后使用反相高效液相色谱(HPLC)将这种富集的胎儿IGF制剂纯化至同质。然而,发现使用HPLC凝胶过滤柱进行色谱分离对于确保纯化肽在储存期间的稳定性至关重要,尽管该步骤并未导致纯化度有任何明显提高。从400ml胎羊血清中最终纯化得到的绵羊胎儿IGF产量为80微克。在对胎儿生长调节素进行氨基末端测序时仅检测到一条多肽链,并且该制剂在凝胶电泳和等电聚焦上均给出单一条带,表明该肽基本纯净。其序列(八个氨基酸残基)与来自人、大鼠和牛源的IGF-II中的相应序列相同。此外,对绵羊胎儿IGF的氨基酸分析显示与其他物种的IGF-II的氨基酸含量非常相似。通过HPLC凝胶过滤估计的纯化肽的分子量约为7000,接近先前纯化的生长调节素的分子量,并且通过色谱聚焦获得的等电点约为pH 6.8。因此,纯化的绵羊胎儿生长调节素似乎与其他物种的IGF-II相似,可能是人类IGF-II在绵羊中的同源物。